We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Portable DNA Sequencer Functions Well in Evaluation Trials

By LabMedica International staff writers
Posted on 05 Apr 2015
Print article
Image: Close up of the MinION nanopore sequencer (Photo courtesy of Dr. Andrew Kilianski, Edgewood Chemical Biological Center).
Image: Close up of the MinION nanopore sequencer (Photo courtesy of Dr. Andrew Kilianski, Edgewood Chemical Biological Center).
Researchers have demonstrated the ability of a handheld nanopore sequencer to accurately identify and differentiate bacterial and viral samples.

The Oxford Nanopore Technologies (Oxford, United Kingdom) MinION nanopore sequencer was recently released to a select group of investigators for evaluation using a variety of sequencing applications.

MinION rapidly determines the sequence of subject DNA through the application of protein nanopore technology. The method is based on a protein channel—only a few nanometers in diameter—through which a single strand of DNA can pass. As the DNA strand passes through the nanopore, it generates a series of characteristic electrical signatures, from which nucleotide bases can be identified, and the sequence of the strand determined. The instrument is powered and operated by a laptop computer via a USB connection.

Some teams of evaluators tested the ability of the MinION to act as a whole genome sequencer and demonstrated that nanopore sequencing has tremendous potential utility. However, the current nanopore technology still has limitations with respect to error-rate, and this is problematic when attempting to assemble whole genomes without secondary rounds of sequencing to correct errors. In the current study, investigators at Edgewood Chemical Biological Center (Edgewood, MD, USA) and Signature Science, LLC (Austin, TX, USA) tested the ability of the MinION to accurately identify and differentiate bacterial and viral samples via directed sequencing of characteristic genes.

They reported in the March 26, 2015, edition of the journal GigaScience that by using a six hour sequencing run time, sufficient data were generated to identify an E. coli sample down to the species level from 16S rDNA amplicons. Three poxviruses (cowpox, vaccinia-MVA, and vaccinia-Lister) were identified and differentiated down to the strain level, despite over 98% identity between the vaccinia strains. The ability to differentiate strains by amplicon sequencing on the MinION was accomplished despite an observed per-base error rate of approximately 30%.

First author Dr. Andrew Kilianski, a researcher at Edgewood Chemical Biological Center, said, "Our findings are important because we have for the first time communicated to the community that this technology can be incredibly useful in its current state. Being able to accurately identify and characterize strains of viruses and bacteria using a mobile platform is attractive to anyone collecting biological samples in the field. And we expect that as the technology improves, the sequencing will generally become cheaper, faster, and more accurate and could have further clinical applications."

Related Links:

Oxford Nanopore Technologies
Edgewood Chemical Biological Center 
Signature Science, LLC 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.